Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Debt Repayments (2022 - 2024)

Ani Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at $291.0 million for Q3 2024.

  • For Q3 2024, Long-Term Debt Repayments rose 19500.0% year-over-year to $291.0 million; the TTM value through Sep 2024 reached $295.5 million, up 39300.0%, while the annual FY2023 figure was $3.0 million, 0.0% changed from the prior year.
  • Long-Term Debt Repayments for Q3 2024 was $291.0 million at Ani Pharmaceuticals, up from $750000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $291.0 million in Q3 2024 and bottomed at -$1.5 million in Q3 2023.
  • The 3-year median for Long-Term Debt Repayments is $750000.0 (2022), against an average of $27.1 million.
  • The largest annual shift saw Long-Term Debt Repayments crashed 300.0% in 2023 before it skyrocketed 19500.0% in 2024.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $750000.0 in 2022, then soared by 300.0% to $3.0 million in 2023, then soared by 9600.0% to $291.0 million in 2024.
  • Per Business Quant, the three most recent readings for ANIP's Long-Term Debt Repayments are $291.0 million (Q3 2024), $750000.0 (Q2 2024), and $750000.0 (Q1 2024).